Molecule exists to explain why biotech moves — not just what happened. Innovation doesn’t advance in a straight line; it’s shaped by a push and pull between public markets, venture capital, and the earliest “phase 0” signals emerging from research.

We break those forces down in a way that is structured, unbiased, and geniunely useful. From discovery and pre-clinical data to funding cycles, M&A behavior, pricing shifts, and policy changes, Molecule connects the dots between biotech’s momentum.

Our goal is simple: create a place where readers can understand where innovation begins, how it gets financed, and what ultimately shapes the industry’s direction.